一分钟看懂
这是一项关于唾液腺癌的II 期研究，登记的药物或干预包括abiraterone combined with dalpiciclib，当前状态为招募中。登记地点显示中国上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
abiraterone combined with dalpiciclib · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine · 上海
公开的入选条件
- * \- Aged 18-75 years, male or female;
- * Patients with histopathologically confirmed salivary gland malignancy of the head and neck: recurrent/metastatic disease without curative-intent therapeutic options (surgery/radiotherapy), or unresectable locally-advanced disease, with at least one measurabl
- * HER-2-negative and AR-positive status determined by immunohistochemistry (IHC);
- * Availability of evaluable tumor tissue (paraffin-embedded specimen obtained within the past 2 years or fresh tumor tissue);
- * ECOG performance status of 0 or 1;
- * Expected survival ≥12 weeks;
- * Adequate major-organ function within 2 weeks prior to study treatment initiation, meeting the following criteria:
- * Bone marrow: haemoglobin ≥100 g/L, white blood cell count ≥4.0 × 10⁹/L or absolute neutrophil count ≥2.0 × 10⁹/L, platelet count ≥100 × 10⁹/L, in the absence of transfusion or colony-stimulating factor support;
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07815522；登记信息更新于 2026-09-11。